Emergent BioSolutions Secures Over $60 Million in Smallpox Countermeasure Contracts

Key Facts

1Emergent BioSolutions secured a $54 million contract from the U.S. government for its VIGIV smallpox treatment.

2The total value of the new contract and international orders exceeds $60 million.

3The U.S. contract is an option exercise from an existing 10-year agreement with the Administration for Strategic Preparedness and Response (ASPR).

Emergent BioSolutions (NYSE: EBS) has announced securing new contracts and orders worth over $60 million for its smallpox medical countermeasure, VIGIV. The primary component is a $54 million contract from the U.S. government, exercised as an option under an existing 10-year agreement. This contract was awarded by the Administration for Strategic Preparedness and Response (ASPR), part of the U.S. Department of Health and Human Services. In addition to the domestic award, the company also secured orders from an unnamed international government partner. These agreements are part of a broader strategy to maintain preparedness against potential smallpox outbreaks. This development provides significant financial visibility for the biotech firm and reinforces its position as a critical government supplier.

Open on chart